CoChat

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors such as pembrolizumab, ipilimumab, and nivolumab, now FDA-approved for use in treating several types of cancer, have been associated with immune-related adverse effects. Specifically, the antibodies targeting the programmed-cell death-1 immune checkpoint, pembrolizumab and nivolumab, have been rarely reported to induce the development of type 1 diabetes mellitus. Here we describe a case of a patient who developed antibody-positive type 1 diabetes mellitus following treatment with pembrolizumab in combination with systemic chemotherapy for metastatic adenocarcinoma of the lung. We will also provide a brief literature review of other rarely reported cases of type 1 diabetes presenting after treatment with pembrolizumab and nivolumab, as well as discussion regarding potential mechanisms of this adverse effect and its importance as these drugs continue to become even more widespread.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00262-016-1913-7

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 121

Metadata

Authors
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F.
Affiliations
  • Northwestern University (US)
  • University of Virginia (US)
Corresponding author
Chae, Young Kwang
Venue
Cancer Immunology, Immunotherapy
Published
2016-10-19
Volume
66
Issue
1
Pages
25-32
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2532961791
Cited by
121
References
34
Citations by year
2026: 4 · 2025: 6 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 15 · 2020: 16 · 2019: 18 · 2018: 18 · 2017: 20
FWCI
10.06
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
pembrolizumab, type 1 diabetes, immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, nivolumab, ipilimumab, lung adenocarcinoma, metastatic cancer, systemic chemotherapy, autoimmune diabetes, drug-induced diabetes
MeSH terms
Aged, Antineoplastic Combined Chemotherapy Protocols, Diabetes Mellitus, Type 1, Humans, Lung Neoplasms, Male, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. https://app.cochat.ai/papers/10.1007/s00262-016-1913-7
The paper
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017). A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-016-1913-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.